MedPath

Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd. logo
🇨🇳China
Ownership
Public, Subsidiary
Established
2017-05-12
Employees
1.4K
Market Cap
-
Website
https://www.mabwell.com
globenewswire.com
·

Renal Cancer Clinical Trial Pipeline Appears Robust With

DelveInsight 's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.
finance.yahoo.com
·

Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech , Allogene Therapeutics , and Merck & Co. Inc . Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100 .
© Copyright 2025. All Rights Reserved by MedPath